GEN Exclusives

More »

GEN News Highlights

More »
Apr 16, 2007

Quest Ponies Up $2B for AmeriPath

  • Quest Diagnostics will take over AmeriPath in an all-cash transaction valued at approximately $2 billion.

    "This acquisition will establish our leading position in cancer diagnostics with a focus on dermatopathology, anatomic pathology, and molecular diagnostics," comments Surya N. Mohapatra, Ph.D., chairman and CEO, Quest. "AmeriPath is respected for its leadership in dermatopathology and anatomic pathology, two of the fastest growing segments in diagnostic testing. Additionally, its specialty laboratories will further strengthen our hospital and esoteric testing business.”

    The transaction is expected to close during the second quarter of 2007, according to Quest. “The acquisition will accelerate Quest Diagnostics' revenue and earnings growth and provide compelling benefits for patients, physicians, hospitals and payers through enhanced customer service and expanded test offerings," notes Dr. Mohapatra. 

    Quest reports that AmeriPath has annualized revenues in excess of $800 million. It predicts that the acquisition will have minimal impact to the company’s 2007 EPS and will be modestly accretive to 2008 EPS.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Companion Animal Care

Do you think Americans spend too much on companion animal care?